<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="3169f903-21fe-21c0-e063-6294a90a2737"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use POTASSIUM CHLORIDE safely and effectively. See full prescribing information for POTASSIUM CHLORIDE.</content>
      <content styleCode="bold"/>
      <br/>
      <br/>
      <content styleCode="bold">POTASSIUM CHLORIDE oral solution </content>
      <br/>
      <content styleCode="bold">Initial U.S. Approval: 1948</content>
   </title>
   <effectiveTime value="20250328"/>
   <setId root="104ccc91-2aaf-4bb7-bb64-77c29413f60e"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="047437707"/>
            <name>ATLANTIC BIOLOGICALS CORP.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="047437707"/>
                        <name>ATLANTIC BIOLOGICALS CORP.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73606" displayName="repack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="17856-1458" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="316a3ce9-b274-7204-e063-6394a90a2b3d"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250328"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="17856-1458" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Potassium Chloride</name>
                        <formCode code="C42986" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Potassium Chloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="69238-1458" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XF417D3PSL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS CITRIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H77VEI93A8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C YELLOW NO. 6</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PDC6A3C0OX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="A2I8C7HI9T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLPARABEN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Z8IX2SC1OH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLPARABEN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1Q73Q2JULR" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CITRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="96K6UQ3ZD4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCRALOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="g" value="3"/>
                              <denominator unit="mL" value="15"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="660YQ98I10" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POTASSIUM CHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="295O53K152" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POTASSIUM CATION</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="15" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43188" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CUP, UNIT-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="72" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="17856-1458-1" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43179" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOX, UNIT-DOSE"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20230920"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA210041" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20180724"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48331" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="orange" xsi:type="CE">
                              <originalText>clear, orange</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLFLAVOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C73406" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORANGE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_05bd146c-fd0d-4a29-ad56-4790e48c5a10">
               <id root="3169f903-21ff-21c0-e063-6294a90a2737"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>
                  <content styleCode="bold">1 INDICATIONS AND USAGE</content>
               </title>
               <text>
                  <paragraph>Potassium chloride is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction are insufficient.</paragraph>
               </text>
               <effectiveTime value="20230920"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Potassium chloride is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction are insufficient. (
 
    <linkHtml href="#LINK_48a0e91b-f312-4b7b-8793-a4243b21b18a">1</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_ecbfa035-9191-405a-b216-f551f85435aa">
               <id root="3169f903-2200-21c0-e063-6294a90a2737"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>
                  <content styleCode="bold">2 DOSAGE AND ADMINISTRATION</content>
               </title>
               <text/>
               <effectiveTime value="20230920"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Dilute prior to administration. (
 
    <linkHtml href="#LINK_bad3028e-2934-469c-a6ac-b06bea7a0cca">2.1,</linkHtml>
                           <linkHtml href="#LINK_60fbab02-dbd0-4ba1-9cde-f1ae9d85a957">5.1</linkHtml>)

   </paragraph>
                        <paragraph>Monitor serum potassium and adjust dosage accordingly (
 
    <linkHtml href="#LINK_d97dfa55-5b33-4b2e-ad38-514436805454">2.2,</linkHtml>
                           <linkHtml href="#LINK_3e99e682-d837-45bb-bb8f-b61d4accbbe8">2.3</linkHtml>)

   </paragraph>
                        <paragraph>
                           <content styleCode="italics">Treatment of hypokalemia:</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Adults: Initial doses range from 40 to 100 mEq/day in 2 to 5 divided doses: limit doses to 40 mEq per dose. Total daily dose should not exceed 200 mEq (
  
     <linkHtml href="#LINK_d97dfa55-5b33-4b2e-ad38-514436805454">2.2</linkHtml>)
 
    </item>
                           <item>Pediatric patients aged birth to 16 years old: 2 to 4 mEq/kg/day in divided doses; not to exceed 1 mEq/kg as a single dose or 40 mEq whichever is lower; if deficits are severe or ongoing losses are great, consider intravenous therapy. Total daily dose should not exceed 100 mEq (
  
     <linkHtml href="#LINK_3e99e682-d837-45bb-bb8f-b61d4accbbe8">2.3</linkHtml>)
 
    </item>
                        </list>
                        <paragraph>
                           <content styleCode="italics">Maintenance or Prophylaxis of hypokalemia:</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Adults: Typical dose is 20 mEq per day (
  
     <linkHtml href="#LINK_d97dfa55-5b33-4b2e-ad38-514436805454">2.2</linkHtml>)
 
    </item>
                           <item>Pediatric patients aged birth to 16 years old: typical dose is 1 mEq/kg/day. Do not exceed 3 mEq/kg/day (
  
     <linkHtml href="#LINK_3e99e682-d837-45bb-bb8f-b61d4accbbe8">2.3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_bad3028e-2934-469c-a6ac-b06bea7a0cca">
                     <id root="3169f903-2201-21c0-e063-6294a90a2737"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.1 Administration and Monitoring</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Monitoring</content>
                        </paragraph>
                        <paragraph>Monitor serum potassium and adjust dosages accordingly. For treatment of hypokalemia, monitor potassium levels daily or more often depending on the severity of hypokalemia until they return to normal. Monitor potassium levels monthly to biannually for maintenance or prophylaxis.</paragraph>
                        <paragraph>The treatment of potassium depletion, particularly in the presence of cardiac disease, renal disease, or acidosis requires careful attention to acid-base balance, volume status, electrolytes, including magnesium, sodium, chloride, phosphate, and calcium, electrocardiograms and the clinical status of the patient. Correct volume status, acid-base balance and electrolyte deficits as appropriate.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Administration</content>
                        </paragraph>
                        <paragraph>Dilute the potassium chloride solution with at least 4 ounces of cold water
 
  <content styleCode="italics">[see
  
   <linkHtml href="#LINK_60fbab02-dbd0-4ba1-9cde-f1ae9d85a957">Warnings and Precautions (5.1)</linkHtml>]
 
  </content>.

 </paragraph>
                        <paragraph>Take with meals or immediately after eating.</paragraph>
                        <paragraph>If serum potassium concentration is &lt; 2.5 mEq/L, use intravenous potassium instead of oral supplementation.</paragraph>
                     </text>
                     <effectiveTime value="20230920"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_d97dfa55-5b33-4b2e-ad38-514436805454">
                     <id root="3169f903-2202-21c0-e063-6294a90a2737"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.2 Adult Dosing</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Treatment of hypokalemia</content>
                        </paragraph>
                        <paragraph>Daily dose range from 40 to 100 mEq. Give in 2 to 5 divided doses; limit doses to 40 mEq per dose. The total daily dose should not exceed 200 mEq in a 24 hour period.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Maintenance or Prophylaxis</content>
                        </paragraph>
                        <paragraph>Typical dose is 20 mEq per day. Individualize dose based upon serum potassium levels.</paragraph>
                        <paragraph>Studies support the use of potassium replacement in digitalis toxicity. When alkalosis is present, normokalemia and hyperkalemia may obscure a total potassium deficit. The advisability of use of potassium replacement in the setting of hyperkalemia is uncertain.</paragraph>
                     </text>
                     <effectiveTime value="20230920"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_3e99e682-d837-45bb-bb8f-b61d4accbbe8">
                     <id root="3169f903-2203-21c0-e063-6294a90a2737"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.3 Pediatric Dosing</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Treatment of hypokalemia</content>
                        </paragraph>
                        <paragraph>Pediatric patients aged birth to 16 years old: The initial dose is 2 to 4 mEq/kg/day in divided doses; do not exceed as a single dose 1 mEq/kg or 40 mEq, whichever is lower; maximum daily doses should not exceed 100 mEq. If deficits are severe or ongoing losses are great, consider intravenous therapy.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Maintenance or Prophylaxis</content>
                        </paragraph>
                        <paragraph>Pediatric patients aged birth to 16 years old: Typical dose is 1 mEq/kg/day. Do not exceed 3 mEq/kg/day.</paragraph>
                     </text>
                     <effectiveTime value="20230920"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_e818cfc8-0d66-4f48-bfc2-8e1ce99f3569">
               <id root="3169f903-2204-21c0-e063-6294a90a2737"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>
                  <content styleCode="bold">3 DOSAGE FORMS AND STRENGTHS</content>
               </title>
               <text>
                  <paragraph>Oral Solution 10%: 1.3 mEq potassium per mL. 
  <br/>  Oral Solution 20%: 2.6 mEq potassium per mL.
 </paragraph>
               </text>
               <effectiveTime value="20230920"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Oral Solution: 10%; 1.3 mEq potassium per mL (
  
     <linkHtml href="#LINK_ed9cc327-a9b2-497e-8154-bd9219fd4770">3</linkHtml>)
 
    </item>
                           <item>Oral Solution: 20%; 2.6 mEq potassium per mL (
  
     <linkHtml href="#LINK_ed9cc327-a9b2-497e-8154-bd9219fd4770">3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_dcf24e1d-77f7-4d91-9b83-2a97595d8d02">
               <id root="3169f903-2205-21c0-e063-6294a90a2737"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>
                  <content styleCode="bold">4 CONTRAINDICATIONS</content>
               </title>
               <text>
                  <paragraph>Potassium chloride is contraindicated in patients on potassium sparing diuretics.</paragraph>
               </text>
               <effectiveTime value="20230920"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Concomitant use with potassium sparing diuretics. (
  
     <linkHtml href="#LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">4</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_029d0bd7-f796-47b8-807e-2e11d0e3833a">
               <id root="3169f903-2206-21c0-e063-6294a90a2737"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>
                  <content styleCode="bold">5 WARNINGS AND PRECAUTIONS</content>
               </title>
               <effectiveTime value="20230920"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Gastrointestinal Irritation:</content>Dilute before use, take with meals (
  
     <linkHtml href="#LINK_60fbab02-dbd0-4ba1-9cde-f1ae9d85a957">5.1</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_60fbab02-dbd0-4ba1-9cde-f1ae9d85a957">
                     <id root="3169f903-2207-21c0-e063-6294a90a2737"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.1 Gastrointestinal Irritation</content>
                     </title>
                     <text>
                        <paragraph>May cause gastrointestinal irritation if administered undiluted. Increased dilution of the solution and taking with meals may reduce gastrointestinal irritation
 
  <content styleCode="italics">[see
  
   <linkHtml href="#LINK_bad3028e-2934-469c-a6ac-b06bea7a0cca">Dosage and Administration (2.1)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20230920"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_ee54f230-f0fa-4b38-b815-6a9760e5947c">
               <id root="3169f903-2208-21c0-e063-6294a90a2737"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">6 ADVERSE REACTIONS</content>
               </title>
               <text>
                  <paragraph>The most common adverse reactions to oral potassium salts are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea.</paragraph>
               </text>
               <effectiveTime value="20230920"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea. (
 
    <linkHtml href="#LINK_9440e503-baf7-441c-991f-439bc85d32c3">6</linkHtml>)

   </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or</content>
                           <content styleCode="bold">
                              <content styleCode="italics">www.fda.gov/medwatch</content>
                           </content>
                           <content styleCode="bold">.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_9888622d-b12e-4eb2-a123-bfcf93d314cc">
               <id root="3169f903-2209-21c0-e063-6294a90a2737"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">7 DRUG INTERACTIONS</content>
               </title>
               <text/>
               <effectiveTime value="20230920"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Potassium sparing diuretics: Avoid concomitant use (
  
     <linkHtml href="#LINK_82fa2d0f-c89b-4eec-be1b-25b5a4438199">7.1</linkHtml>)
 
    </item>
                           <item>Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia (
  
     <linkHtml href="#LINK_3a48e7de-33b9-453a-87c5-31602ddb4039">7.2</linkHtml>)
 
    </item>
                           <item>Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia (
  
     <linkHtml href="#LINK_04a5f763-7953-4f1d-acc0-eeb78babea5e">7.3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_82fa2d0f-c89b-4eec-be1b-25b5a4438199">
                     <id root="3169f903-220a-21c0-e063-6294a90a2737"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.1 Potassium-Sparing Diuretics</content>
                     </title>
                     <text>
                        <paragraph>Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use.</paragraph>
                     </text>
                     <effectiveTime value="20230920"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_3a48e7de-33b9-453a-87c5-31602ddb4039">
                     <id root="3169f903-220b-21c0-e063-6294a90a2737"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.2 Renin-Angiotensin-Aldosterone System Inhibitors </content>
                     </title>
                     <text>
                        <paragraph>Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy.</paragraph>
                     </text>
                     <effectiveTime value="20230920"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_04a5f763-7953-4f1d-acc0-eeb78babea5e">
                     <id root="3169f903-220c-21c0-e063-6294a90a2737"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)</content>
                     </title>
                     <text>
                        <paragraph>NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. Closely monitor potassium in patients on concomitant NSAIDs.</paragraph>
                     </text>
                     <effectiveTime value="20230920"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_4871bcf2-8ffb-4b90-8f71-32067b4d14f7">
               <id root="3169f903-220d-21c0-e063-6294a90a2737"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>
                  <content styleCode="bold">8 USE IN SPECIFIC POPULATIONS</content>
               </title>
               <text/>
               <effectiveTime value="20230920"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Cirrhosis: Initiate therapy at the low end of the dosing range
  
     <linkHtml href="#LINK_3e795269-3af6-45cf-93cb-ca6409fe48d1">(8.6)</linkHtml>
                           </item>
                           <item>Renal Impairment: Initiate therapy at the low end of the dosing range
  
     <linkHtml href="#LINK_2732e646-4299-4c45-af65-776a3cb34c20">(8.7)</linkHtml>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_9192eee9-8507-4f6a-9fe3-93ead4b9a5a8">
                     <id root="3169f903-220e-21c0-e063-6294a90a2737"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>
                        <content styleCode="bold">8.1 Pregnancy</content>
                     </title>
                     <text>
                        <paragraph>There are no human data related to use of potassium chloride during pregnancy, and animal studies have not been conducted. Potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm.</paragraph>
                        <paragraph>The background risk for major birth defects and miscarriage in the indicated population is unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20% respectively.</paragraph>
                     </text>
                     <effectiveTime value="20230920"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_d0573cf9-4079-4813-9876-a46c257844ef">
                     <id root="3169f903-220f-21c0-e063-6294a90a2737"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>
                        <content styleCode="bold">8.2 Lactation</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>The normal potassium ion content of human milk is about 13 mEq per liter. Since potassium from oral supplements such as potassium chloride becomes part of the body potassium pool, as long as body potassium is not excessive, the contribution of potassium chloride supplementation should have little or no effect on the level in human milk.</paragraph>
                     </text>
                     <effectiveTime value="20230920"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_464f4033-4222-430c-adb7-1045fcd01f81">
                     <id root="3169f903-2210-21c0-e063-6294a90a2737"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.4 Pediatric Use</content>
                     </title>
                     <text>
                        <paragraph>The safety and effectiveness of potassium chloride have been demonstrated in children with diarrhea and malnutrition from birth to 16 years.</paragraph>
                     </text>
                     <effectiveTime value="20230920"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ea46630b-35d1-4572-b3c5-8793c688b37f">
                     <id root="3169f903-2211-21c0-e063-6294a90a2737"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.5 Geriatric Use</content>
                     </title>
                     <text>
                        <paragraph>Clinical studies of potassium chloride did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</paragraph>
                        <paragraph>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</paragraph>
                     </text>
                     <effectiveTime value="20230920"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_3e795269-3af6-45cf-93cb-ca6409fe48d1">
                     <id root="3169f903-2212-21c0-e063-6294a90a2737"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">8.6 Cirrhosis</content>
                     </title>
                     <text>
                        <paragraph>Patients with cirrhosis should usually be started at the low end of the dosing range, and the serum potassium level should be monitored frequently
 
  <content styleCode="italics">[see
  
   <linkHtml href="#LINK_87471a6b-c62d-42d4-84bf-29d682ae10e4">Clinical Pharmacology (12.3)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20230920"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_2732e646-4299-4c45-af65-776a3cb34c20">
                     <id root="3169f903-2213-21c0-e063-6294a90a2737"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">8.7 Renal Impairment</content>
                     </title>
                     <text>
                        <paragraph>Patients with renal impairment have reduced urinary excretion of potassium and are at substantially increased risk of hyperkalemia. Patients with impaired renal function, particularly if the patient is on ACE inhibitors, ARBs, or nonsteroidal anti-inflammatory drugs should usually be started at the low end of the dosing range because of the potential for development of hyperkalemia. The serum potassium level should be monitored frequently. Renal function should be assessed periodically.</paragraph>
                     </text>
                     <effectiveTime value="20230920"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_2fd73915-f3de-46ef-8040-41d7843aff7f">
               <id root="3169f903-2214-21c0-e063-6294a90a2737"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>
                  <content styleCode="bold">10 OVERDOSAGE</content>
               </title>
               <effectiveTime value="20230920"/>
               <component>
                  <section ID="LINK_5e62a4f1-ca42-44fe-a2f7-878d74232133">
                     <id root="3169f903-2215-21c0-e063-6294a90a2737"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">10.1 Symptoms</content>
                     </title>
                     <text>
                        <paragraph>The administration of oral potassium salts to persons with normal excretory mechanisms for potassium rarely causes serious hyperkalemia. However, if excretory mechanisms are impaired or if potassium is administered too rapidly potentially fatal hyperkalemia can result.</paragraph>
                        <paragraph>Hyperkalemia is usually asymptomatic and may be manifested only by an increased serum potassium concentration (6.5 to 8.0 mEq/L) and characteristic electrocardiographic changes (peaking of T-waves, loss of P-waves, depression of S-T segment, and prolongation of the QT-interval). Late manifestations include muscle paralysis and cardiovascular collapse from cardiac arrest (9 to 12 mEq/L).</paragraph>
                        <paragraph>
                           <content styleCode="bold"/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230920"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_235db144-ccdc-494f-82d3-fefeed3a57dc">
                     <id root="3169f903-2216-21c0-e063-6294a90a2737"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">10.2 Treatment</content>
                     </title>
                     <text>
                        <paragraph>Treatment measures for hyperkalemia include the following:</paragraph>
                        <list listType="ordered" styleCode="Arabic">
                           <item>Monitor closely for arrhythmias and electrolyte changes.</item>
                           <item>Eliminate foods and medications containing potassium and of any agents with potassium-sparing properties such as potassium-sparing diuretics, ARBS, ACE inhibitors, NSAIDS, certain nutritional supplements and many others.</item>
                           <item>Administer intravenous calcium gluconate if the patient is at no risk or low risk of developing digitalis toxicity.</item>
                           <item>Administer intravenously 300 to 500 mL/hr of 10% dextrose solution containing 10 to 20 units of crystalline insulin per 1000 mL.</item>
                           <item>Correct acidosis, if present, with intravenous sodium bicarbonate.</item>
                           <item>Use exchange resins, hemodialysis, or peritoneal dialysis.</item>
                        </list>
                        <paragraph>In patients who have been stabilized on digitalis, too rapid a lowering of the serum potassium concentration can produce digitalis toxicity.</paragraph>
                     </text>
                     <effectiveTime value="20230920"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_a25314c0-9185-4340-bc9c-06fdd32206f9">
               <id root="3169f903-2217-21c0-e063-6294a90a2737"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>
                  <content styleCode="bold">11 DESCRIPTION</content>
               </title>
               <text>
                  <paragraph>Potassium chloride, USP is a white granular powder. It is freely soluble in water and insoluble in alcohol. Chemically, potassium chloride, USP is K-Cl with a molecular mass of 74.55.</paragraph>
                  <paragraph>Oral Solution 10%: Each 15 mL of solution contains 1.5 g of potassium chloride, USP and the following inactive ingredients: citric acid anhydrous, FD&amp;C Yellow #6, glycerin, methylparaben, natural/artificial orange flavor, propylene glycol, propylparaben, purified water, sodium citrate, sucralose.</paragraph>
                  <paragraph>Oral Solution 20%: Each 15 mL of solution contains 3 g of potassium chloride, USP and the following inactive ingredients: citric acid anhydrous, FD&amp;C Yellow #6, glycerin, methylparaben, natural/artificial orange flavor, propylene glycol, propylparaben, purified water, sodium citrate, sucralose.</paragraph>
               </text>
               <effectiveTime value="20230920"/>
            </section>
         </component>
         <component>
            <section ID="LINK_d5a69791-4f3b-4d1b-af19-6100f903670d">
               <id root="3169f903-2218-21c0-e063-6294a90a2737"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">12 CLINICAL PHARMACOLOGY</content>
               </title>
               <effectiveTime value="20230920"/>
               <component>
                  <section ID="LINK_72d1f172-82aa-4f21-abb0-9c1302a40829">
                     <id root="3169f903-2219-21c0-e063-6294a90a2737"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>
                        <content styleCode="bold">12.1 Mechanism of Action</content>
                     </title>
                     <text>
                        <paragraph>The potassium ion (K
 
  <sup>+</sup>) is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity; the transmission of nerve impulses; the contraction of cardiac, skeletal, and smooth muscle; and the maintenance of normal renal function.

 </paragraph>
                        <paragraph>The intracellular concentration of potassium is approximately 150 to 160 mEq per liter. The normal adult plasma concentration is 3.5 to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane.</paragraph>
                        <paragraph>Potassium is a normal dietary constituent, and under steady-state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. The usual dietary intake of potassium is 50 to 100 mEq per day.</paragraph>
                     </text>
                     <effectiveTime value="20230920"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_17fd4dd2-0529-477b-907a-3a9739448100">
                     <id root="3169f903-221a-21c0-e063-6294a90a2737"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.3 Pharmacokinetics</content>
                     </title>
                     <text>
                        <paragraph>Based on published literature, the rate of absorption and urinary excretion of potassium from KCl oral solution were higher during the first few hours after dosing relative to modified release KCl products. The bioavailability of potassium, as measured by the cumulative urinary excretion of K
 
  <sup>+</sup>over a 24 hour post dose period, is similar for KCl solution and modified release products.

 </paragraph>
                     </text>
                     <effectiveTime value="20230920"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_4b96fed0-ec15-410a-ac9b-4ef5fdb15b10">
               <id root="3169f903-221b-21c0-e063-6294a90a2737"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>
                  <content styleCode="bold">16 HOW SUPPLIED/STORAGE AND HANDLING</content>
               </title>
               <text>
                  <paragraph>Potassium chloride oral solution USP,
 
  <content styleCode="bold">20% (40 mEq per 15 mL)</content>is supplied as a clear, orange colored solution available as follows: Cups of 15 mL   NDC 17856-1458-01

 </paragraph>
                  <paragraph/>
                  <paragraph>
                     <content styleCode="bold">Storage</content>
                  </paragraph>
                  <paragraph>Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP.</paragraph>
                  <paragraph>PROTECT from LIGHT and FREEZING.</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>Distributed by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">ATLANTIC BIOLOGICALS CORP.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">MIAMI, FL 33179</content>
                  </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20230920"/>
            </section>
         </component>
         <component>
            <section ID="LINK_879fa56a-051c-4ac5-9988-f7a01b7051fb">
               <id root="316a39e9-3e14-671c-e063-6294a90abadd"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_316a2cab-7b02-69b5-e063-6394a90a6a5a"/>
                  </paragraph>
               </text>
               <effectiveTime value="20230920"/>
               <component>
                  <observationMedia ID="img_316a2cab-7b02-69b5-e063-6394a90a6a5a">
                     <text>1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="17856-1458-01 Case Label (1).jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>